IRE1
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S7272 | 4μ8C | <1 mg/mL | 19 mg/mL | <1 mg/mL |
| S7771 | STF-083010 | <1 mg/mL | 63 mg/mL | <1 mg/mL |
| S8286 | MKC-3946 | <1 mg/mL | 38 mg/mL | 3 mg/mL |
| S8658 | kira6 | <1 mg/mL | 60 mg/mL | 60 mg/mL |
- IRE1 Inhibitors (4)
- New IRE1 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7272 |
4μ8C4μ8C is a potent and selective IRE1 Rnase inhibitor with IC50 of 76 nM. |
||
| S7771 |
STF-083010STF-083010 is a specific IRE1α endonuclease inhibitor without affecting its kinase activity. |
The effect of TUDCA and STF-083010 on mouse decidualization.(B) The average weight of implantation sites on day 8 under TUDCA treatment.(D) The effect of TUDCA treatment on the weight of deciduoma. (F) The average weight of implantation sites on day 8 under STF-083010 treatment. (H) The effect of STF-083010 treatment on the weight of deciduoma. (I) The effect of TUDCA on the mRNA expression of Dtprp in vitro decidualization. (J) The effect of STF-083010 on the mRNA expression of Dtprp in vitro decidualization. Data are presented as the mean ± SD, *p < 0.05. |
|
| S8286 |
MKC-3946MKC3946 is a potent and soluble IRE1α endoribonuclease domain inhibitor which triggered modest growth inhibition in multiple myeloma cell lines, without toxicity in normal mononuclear cells. |
||
| S8658New |
kira6kira6 is a potent type II IRE1α kinase inhibitor with an IC50 of 0.6 μM. It dose-dependently inhibits IRE1α(WT) kinase activity, XBP1 RNA cleavage, Ins2 RNA cleavage and oligomerization. |
